Radiation-induced pulmonary fibrosis (RIPF) is a late side effect of thoracic radiotherapy, causing significant morbidity and mortality. Here, we provide the first evidence that an vascular EndMT caused by initial vascular hypoxic damage leads to RIPF development, prior to EMT in aveoli. Moreover, HIF1-α-related EndMT was prominently observed in the RIPF tissues of lung cancer patients received radiotherapy. In addition, we show that a promising HIF1-α-inhibitory agent (2-ME, currently in phase I/II trials as several cancer therapeutics) prevents RIPF by inhibiting vascular EndMT. In this study, we suggest that a vascular hypoxia-related EndMT may provide an important initial target for RIPF prevention. Concomitant with the EndMT, we detected vascular endothelial-cell-specific hypoxic damage in the irradiated lung tissues. In human pulmonary artery endothelial cells (HPAECs), the radiation-induced EndMT via activation of TGFβ-R1/Smad signaling was dependent on HIF1-α expression. A novel HIF1-α inhibitor, 2-Methoxyestradiol (2-ME), inhibited the irradiation-induced EndMT via downregulation of HIF1-α-dependent Smad signaling. In vivo, 2-ME inhibited the vascular EndMT, and decreased the collagen deposition associated with RIPF. Furthermore, HIF1-α-related EndMT was observed also in human RIPF tissues.
Introduction
Approximately 60% of non-small-cell lung cancer (NSCLC) patients receive radiation therapy (RT). Unfortunately, during conventional radiotherapy (RT) or stereotactic body radiation therapy (SBRT), lung complications such as pneumonitis and fibrosis can cause significant morbidity in cancer survivors. Radiation-induced pulmonary fibrosis (RIPF) triggers physiological abnormalities (1) (2) (3) . Despite the pressing medical need, little progress has been made to mitigate the radiation-induced pneumonitis. In the past, several medications have been developed to reduce radiation pneumonitis such as corticosteroids, amifostine, ACE inhibitors or angiotensin II type 1 receptor blockers, pentoxifylline, melatonin, carvedilol, and a manganese superoxide dismutase-encoding plasmid delivered in liposomes (4) . Unfortunately, however, their efficacy has been found to be unsatisfactory.
Lung fibrosis develops 6-12 months after lung irradiation, and is characterized by fibroblast proliferation with excessive extracellular matrix (ECM) deposition. It has been demonstrated that the radiation-induced lung fibrosis is preceded by vascular damages within a few weeks of irradiation, such as narrowing and obliteration of capillaries by endothelial cell (EC) swelling, growth of new fibrin plugs, and endothelial hyperplasia, particularly in larger vessels, both arteries and veins (5) . Depletion of functional microvasculature would inevitably lead to tissue ischemia and hypoxia.
Although reactive oxygen species (ROS), transforming growth factor-beta (TGF-β), inflammatory cytokines, and hypoxia have been known to participate in the development of chronic fibrosis in the lung, the precise mechanism as to how the initial radiation injuries progress to chronic fibrosis has been elusive (1, 6) . Hypoxia has been implicated in radiationinduced lung injuries, including inflammatory and fibrogenic responses. Fleckenstein et al. (7) reported that tissue hypoxia after irradiation was associated with increase in oxygen consumption due to a significant increase in macrophage activation, which in turn caused Author Manuscript Published OnlineFirst on April 24, 2015; DOI: 10.1158/1078-0432.CCR- continuous production of ROS. It is likely that the elevation of ROS production stimulates the synthesis of fibrogenic and angiogenic cytokines, thereby triggering chronic radiationinduced lung injury. However, the precise mechanism by which hypoxia affects radiationinduced lung injuries remains unclear.
Activated myofibroblasts play central roles in the production of collagen and ECM proteins during pulmonary fibrosis. Myofibroblasts are derived from various different cell types-including resident stromal fibroblasts, bone-marrow-derived fibrocytes, and the mesenchymal transition of epithelial cells (the epithelial-to-mesenchymal transition, or EMT) (8) . Several studies have shown that alveolar type II epithelial cells undergo EMT during development of pulmonary fibrosis, including RIPF (9, 10) . Recently, the endothelial-tomesenchymal transition (EndMT) has been suggested to give rise to fibroblasts during fibrosis of the heart and kidney, and in cancer (8, 11, 12) . Hashimoto and colleagues (13) demonstrated that EndMT might also serve as a source of fibroblasts in bleomycin-induced pulmonary fibrosis.
The EndMT is characterized by loss of cell-cell junctions and the acquisition of invasive and migratory phenotypes. Mesenchymal cell markers such as α-smooth muscle actin (α-SMA), fibroblast-specific protein-1 (FSP-1), and vimentin are upregulated. On the other hand, endothelial cell-specific markers including CD31 and vascular endothelial (VE)-cadherin are downregulated. There is increasing evidence that TGF-β signaling and the transcriptional activators Snail and Twist are important regulators of the EndMT in pulmonary fibrosis. However, their precise role in the radiation-induced pulmonary fibrosis has not been clearly understood. Although vascular dysfunctions are well-known to play important roles in the pathogenesis of radiation injury in normal tissues (14, 15) , the origins of such dysfunctions remain unclear. We previously reported that radiation-induced atherosclerosis was associated with EndMT. Especially, EC dysfunction was associated with
Research. loss of thromboresistance and increases in cytokine levels. In irradiated human tissues, the prominent fibrosis developing around vascular lesions was characterized by collagen and fibroblast deposition (1, 14) .
Here, we report that during the development of RIPF in mouse lung (1) endothelialspecific hypoxic damage was evident prior to formation of fibrotic lesions. In particular, (2) EndMT occurred principally in large vessels, accompanied by hypoxic damage, and finally, (3) the EndMT appeared prior to the development of EMT in alveoli.
Together, our data demonstrated that initial hypoxic vascular damage caused by irradiation leads to chronic pulmonary fibrosis, and that the EndMT may be a novel target for prevention of RIPF.
Research. 
Methods

Mice and irradiation
All procedures were approved by the Institutional Animal Care and Use Committee of the Korea Institute of Radiological and Medical Sciences, and the Yonsei University Medical School. Radiation was delivered using an X-RAD 320 platform (Precision X-ray, North Branford, CT) as described previously (16) . The left lungs of 10-week-old male C57BL/6 mice were irradiated using a 7-mm-diameter field or a 3-mm-diameter field.
ALK5 inhibitor II (Santa Cruz Biotechnology, Dallas, TX) was dissolved in DMSO, further diluted in distilled water, and administrated intraperitoneally (25 mg/kg).
2-ME (Selleckchem, Houston, TX) was dissolved in DMSO and further diluted in 30% (w/v) PEG-400 with 1% (v/v) Tween 80 prior to intraperitoneal injection (60 mg/kg).
Tissue histology and immunohistochemical staining
Mice were euthanized and lung tissues harvested and fixed in 10% (v/v) neutral buffered formalin prior to preparation of paraffin sections. Paraffin-embedded sections were deparaffinized and stained with hematoxylin and eosin (H&E; Sigma-Aldrich), or using a Masson's trichrome stain kit (Sigma-Aldrich) to detect collagen.
Prior to immunohistochemistry, deparaffinized sections were boiled in 0.1 M citrate buffer (pH 6.0) for 30 min and next incubated with 0.3% (v/v) hydrogen peroxide in methanol for 15 min. Sections were blocked in normal horse serum at room temperature for 30 min and immunostained overnight at 4˚C with primary antibodies against CD31 (1:100; Santa Cruz), α-SMA (1:100; Abcam, Cambridge, MA), Pro-SPC (1:2,000; Millipore, Schwalbach, Germany), CA9 (1:1,000; Novus Biologicals, Littleton, CO), and HIF1-α (1:100; Santa Cruz). The target proteins were visualized using ABC and DAB kits (Vector Laboratories, Burlingame, CA) and counterstained with hematoxylin. For
Research. immunofluorescence staining, sections stained with primary antibodies were incubated with appropriate fluorescently labeled secondary antibodies (1:250; Molecular Probes, Eugene, OR) and counterstained with 4,6-diamidino-2-phenylindole dihydrochloride (DAPI; 3 µM).
Images were obtained using a Zeiss microscope. Additional immunohistochemical analyses were performed as described previously (17) .
Human tissues analysis
The clinical pathological characteristics of the patients analyzed in this study are summarized in Supplementary Table1. The study on specimens of RIPF from patients was approved by Severance Hospital, Yonsei University. Immunostaining, was done for CD31 (1:100; Santa Cruz), α-SMA (1:100; Abcam) and HIF1-α (1:100; Santa Cruz). In addition, tissue microarray including three normal lung tissues was purchased from Biocompare (South San Francisco, CA ). 
Cell culture and treatment
HPAECs
In vitro tests
Immunoblotting was performed as described previously (18) TGF-β1 released into culture medium was measured using a human TGF-β1 ELISA kit (Enzo Life Sciences, Farmingdale, NY) according to the manufacturer's instructions.
Statistical analyses
Student's t-test and analysis of variance (ANOVA) were used to explore the statistical significance of differences between experimental groups. Statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad Software, Inc., San Diego, CA).
Results
The Pattern of Collagen Deposition in RIPF
To study RIPF in mouse lungs, we used three different irradiation doses to different tissue volumes, reflecting the various forms of radiotherapy (16) . To examine fibrosis development, lung sections prepared at various times after irradiation were stained with Masson's trichrome. When 20 Gy was delivered using a large-beam collimator (7-mm-diameter field)
to the left lungs of mice, the collagen deposition was significantly elevated 6 months later, and substantial amounts of fibrotic tissue were noted at 9 months post-irradiation ( Fig. 1A and Supplementary Fig. S1A ). This fibrosis pattern after 20 Gy irradiation was compared with that after ablative focal irradiation with 50 or 90 Gy delivered using a micro-beam collimator (3-mm-diameter field) ( Fig. 1A and Supplementary Fig. S1B ). The collagen deposition in lungs receiving 50 Gy employing the 3-mm collimator rose slightly 2 months after irradiation, and then rose markedly at 6 months (Fig. 1A) . After focal delivery of 90 Gy, significant collagen deposition occurred in the vessels in two weeks, which then significantly increased at 4 weeks, indicative of late-stage fibrosis (Fig. 1A) .
Interestingly, collagen deposition caused by the three irradiation models commenced principally around blood vessels, especially arteries, but not alveolar capillaries, prior to the development of substantial fibrosis. Early collagen deposition was rather vascular-specific, particularly at 3 months after 20 Gy irradiation, 2 months after 50 Gy, and 2 weeks after 90
Gy irradiation (Fig. 1A) . These results indicated that collagen deposition around vessels may be important in the development of RIPF.
EndMT during Development of RIPF
We showed previously that EndMT of human aortic endothelial cells was associated with radiation-induced atherosclerotic tissues (15) . To examine the role of EndMT in fibrosis in Under all three test conditions (20, 50 , and 90 Gy), co-localization of α-SMA and CD31 was evident during the development of RIPF (Fig. 1B) . A significant increase in the colocalization was evident 2 months after 20 Gy irradiation (Fig. 1B) . The extent of overlapping signal (co-localization) steadily increased up to 9 months and decreased at 12 months, at the time of late-stage fibrosis (Fig. 1B, right AE II cells did not express α-SMA in the early stages of RIPF, indicating that EMT was not active when EndMT commenced (Fig. 1B and Supplementary Fig. S2 ). EMT of AE II cells was prominent at the time of development of substantial fibrosis, particularly at 9 and 12 months after 20 Gy irradiation: 4 and 6 months after 50 Gy: and 3 and 4weeks after 90 Gy irradiation ( Supplementary Fig. S2B ). EMT gradually increased in extent until the late stage of RIPF was attained..
Together, the data suggest that the radiation-induced vascular EndMT prior to EMT may provide an important initial target for prevention of RIPF.
Radiation-induced EndMT via TGF-β Receptor/Smad Signaling
The mechanism of irradiation-induced EndMT was investigated with human pulmonary artery endothelial cells (HPAECs) in vitro. As shown in Fig. 2A , after irradiation with 10Gy, the expression of fibroblast markers including vimentin, FSP1, and α-SMA was upregulated and that of endothelial cell markers including VEGFR1, VEGFR2, CD31, and VE-cadherin was downregulated. The immunofluorescence assay showed that irradiation increased the level of FSP1 and decreased that of CD31. Also, irradiation increased the levels of MMP9 and collagen, indicating that radiation triggered EndMT in HPAECs. In addition, irradiation induced progressive increase in the levels of ICAM-1, VCAM-1, and E-selectin, indicating that the ECs were activated and underwent phenotypic changes ( Fig. 2A) .
The irradiation-induced EndMT developed in a radiation dose-dependent manner.
After 10 Gy irradiation, the expression of α-SMA increased continuously from day 2 to 7.
The level of CD31 slightly decreased by 4 h, and then progressively decreased from day 2 to
Research. (Fig. 2B) . The increase in α-SMA level and decrease in CD31 level after irradiation with 2 Gy or 5 Gy were apparently less than those after 10 Gy irradiation.
It has been reported that EndMT-derived cells produce various growth factors including TGF-β (11). We investigated whether the cells induced to enter EndMT by irradiation release TGF-β by performing ELISA assays of the culture supernatants of various human pulmonary cell lines. Although human pulmonary fibroblast (HPF) cells secreted more TGF-β than did ECs before irradiation, ECs (HPAECs and HPMECs, Human pulmonary microvascular endothelial cells) released more TGF-β than did any other cell line tested, 2 days after 10 Gy irradiation (Fig. 2C) . Thus, we concluded that ECs are more sensitive to radiation-induced fibroblastic changes than are other cell lines.
It has been demonstrated that TGF-β enhances Smad3 transcriptional activity and that Notch and rhBMP-7 are important modulators of the EndMT occurring during tissue fibrosis (8, 12, 22) As it has been reported that TGF-β plays a key role in RIPF, we explored whether the signaling cascade triggered by the TGF-β receptor was associated with the radiation-induced EndMT in human pulmonary artery endothelial cells (HPAECs). As shown in Fig. 2A , the expression of TGF-β receptor 1, and the extent of Smad3 phosphorylation, increased during the radiation-induced EndMT. Immunofluorescence test showed that the addition of TGF-β-R1 inhibitor attenuated the fall in VE-cadherin level and the rise in FSP-1 level triggered by the radiation-induced EndMT (Fig. 2D, left) . Immunoassay revealed that the increases in α-SMA and vimentinlevels were inhibited by the TGF-β-R1 inhibitor (Fig. 2D, right ) .
Next, to examine whether the TGF-β-R1 inhibitor reduces EndMT during RIPF development, we irradiated thoracic regions of C57BL/6 mice with 16 Gy. In line with the in vitro data, trichrome staining showed that the TGF-β-R1 inhibitor reduced the extent of RIPF in vivo, attenuating irradiation-induced collagen deposition in vascular regions (Fig. 2E, top) .
Research. Consistently, vascular EndMT lesions that appeared during RIPF were significantly decreased by the injection of the TGF-β-R1 inhibitor (Fig. 2E, bottom) Taken together, the data strongly suggest that irradiation-induced EndMT features in the development of RIPF and may be a potential new target for reducing or eliminating RIPF.
Implication of Hypoxic Damage to Endothelial Cells in the Development of Irradiationinduced Fibrosis
As significant fibrosis and EndMT around vessels were evident during the development of RIPF, we sought to define the EC-specific damage pattern triggered by irradiation.
Interestingly, we observed that hypoxic damage specific to vascular ECs occurs prior to the appearance of substantial fibrosis under all three irradiation conditions by immunostaining for CA9 as a hypoxic marker (Fig. 3A) . In the fibrotic stage, hypoxic damage seemed to have propagated to all tissues. Because the time of appearance of EC-specific hypoxic damage was similar to that of development of the EndMT, thus before the formation of fibrotic tissue, we suggest that radiation-induced hypoxic damage to vascular ECs may be directly associated with the EndMT, leading to chronic fibrosis. Consistent with this hypothesis, HIF1-α positive-endothelial cells were observed in irradiated vessels (Fig. 3B) 
Hypoxia-induced EndMT involves TGFβ-RΙ/Smad signaling in RIPF
HPAECs exhibited high levels of CA9 and actin stress fibers 3days after 10 Gy irradiation (Fig. 3C, top) . Staining with GFP-phalloidin revealed the presence of filamentous actin, one of the hallmarks of EndMT (the filaments form actin stress fibers) (23) . Western blot assay also revealed an increase in HIF1-α expression, and a subsequent rise in the α-SMA level during 7 days after irradiation in HPAECs (Fig. 3C, bottom) Research. 
To elucidate the role of EC-specific hypoxic damage in the irradiation-induced EndMT, we exposed HPMECs to hypoxia (1% [v/v] O 2 ) for 1-7 days. The expression of HIF1-α increased from 6 to 120 h of exposure to hypoxia, and the level of CD31 decreased while α-SMA expression increased from 24 h. As the EndMT commenced after an exposure to hypoxia for 24 h, phosphorylation of Smad3 was significantly increased and expression of TGF-β receptor I and Snail1 were significantly increased (Fig. 3D) . Immunofluorescence data showed that the hypoxia-induced morphological and phenotypic changes were consistent with EndMT phenotype. The exposure to hypoxia caused cells to become elongated, and increased filamentous actin formation and Smad2/3 phosphorylation in the cells treated with control-siRNA (Fig. 3E) . On the other hand, the cells treated with Smad3-siRNA did not display EndMT phenotype, and exhibited reduced Smad3 phosphorylation under hypoxia. Similar results were found by immunoassay (Fig. 3E, right) . These data indicated that hypoxia, like irradiation, induces EndMT via TGF-β receptor I/Smad signaling. To assess the contribution of HIF1-α to the irradiation-induced EndMT, we transfected control-siRNA or HIF1-α-specific siRNA into HPAECs. HIF1-α siRNA prevented the decrease in VE-cadherin level and increases in CA9 and filamentous actin levels (Fig. 3F, top) . Immunoblotting also showed that HIF1-α knockdown reduced the irradiation-induced phosphorylation of Smad2/3 and the increases in α-SMA and vimentin expression, compared to control siRNA-treated cells (Fig. 3F, bottom) .
Taken together, these findings suggest that in HPAECs, radiation-induced hypoxia triggers
EndMT via HIF1-α-mediated activation of TGF-β receptor I/Smad signaling.
2-ME Inhibits Radiation-induced EndMT during Development of RIPF
Analogs of 2-methoxyestradiol (2-ME) are promising HIF1-α-inhibitory agents, and are under active clinical development (24) . Several mechanisms have been suggested to account for the action of 2-ME ; disruption of microtubules by binding to the colchicine-binding site of tubulin (25) and inhibition of TGF-β-mediated collagen synthesis, α-SMA production, and Smad2/3 phosphorylation (25). These possible mechanisms would all exert inhibitory effects on the HIF1-α-dependent EndMT prior to development of RIPF, and we thus studied the effect of 2-ME on the irradiation-induced EndMT in vitro. Pretreatment of HPAECs with 2-ME inhibited the development of irradiation-induced EndMT phenotype. 2-ME also blocked filamentous actin formation, increased CA9 expression and the loss of VE-cadherin (Fig. 4A,   top ). In addition, 2-ME inhibited HIF1-α expression, phosphorylation of Smad2/3 and increases in α-SMA during irradiation-induced EndMT (Fig. 4A, bottom) .
Moreover, in vivo, treatment with 2-ME markedly reduced the vascular deposition of collagen associated with RIPF development and increase in HIF1-α expression in vascular ECs after thoracic irradiation (Fig. 4B) . Simultaneously, 2-ME inhibited the EndMT, as assessed by the extent of co-localization of α-SMA and CD31 in vascular ECs of irradiated lung tissue. Also, 2-ME inhibited the EndMT, with a concomitant increase in HIF1-α levels in vascular ECs (Fig. 4B) , followed by decrease of the EMT occurrence and substantial fibrotic phase in the irradiated lung tissue (Supplementary Fig. S3 ). In addition, treatment with 2-ME significantly reduced RIPF in the lung irradiated with 90 Gy (3-mm collimator) ( Supplementary Fig. S4 ).
In conclusion, we suggest that HIF1-α expression and the EndMT phenotype may play important roles in the development of RIPF, and that 2-ME may be useful to prevent RIPF.
HIF1-α is upregulated on vascular EndMT in the fibrotic regions of irradiated human lung tissue
Next, we examined whether HIF1-α expression is upregulated on vascular ECs and concomitantly, EndMT occurs in radiation-induced lung fibrotic tissues of human patients In the present study, we investigated the development of RIPF in mouse caused by three irradiation conditions. Delivery of 90 or 50 Gy with a micro-beam collimator (3 mm in diameter) to left lungs induced RIPF in 2 weeks and 6 months later, respectively (Fig. 1A) .
Delivery of 20 Gy through a 7-mm-diameter beam collimator to left lungs induced RIPF in 9 months (Fig. 1A) . EndMT accompanying phenotypic alterations during development of RIPF was common to all irradiation conditions (Fig. 1B and Supplementary Fig. S2 ). Therefore, we suggest that minimizing of the EndMT may be effective to counter RIPF developing after various thoracic radiotherapies.
It is well-known that radiation-induced vascular damage plays an important role in the radiation-induced complications of normal tissue (14, 33) . The radiosensitivity of various blood vessels has been shown to be dependent on vessel types: radiosensitivity decreases in order of capillaries > small arteries > medium-sized arteries > large arteries > small veins > large veins (33) . Vascular fibrosis develops principally in arterioles, arteries, and large veins.
The EC response in normal tissues to irradiation is associated with early fibrogenesis. (5, 34) .
Thus, the preventive measure of EC damage is likely to reduce vascular damage during the early phases of tissue injury, and minimizes the late damage in irradiated normal tissues (35) . Previously, Molteni et al. (35) reported that pulmonary damage progressed following endothelial detachment and blebs formation several days after 20 Gy irradiation in rats and severe arteritis and interstitial collagen deposition occurred 3 months after the irradiation.
Kolesnick et al. found that apoptotic death of endothelial cells were evident in mouse lungs 10 h after whole-body irradiation with 20 Gy (36). We also observed that whole-body (1Gy, 5 times) or thoracic (25 Gy) irradiation of mice induced apoptosis and detachment of lung endothelial cells several days later (Supplementary Fig. S6 ).
In the present study, we focused on the vascular ECs that survived and formed pulmonary vascular structures in irradiated lungs because we hypothesized that the surviving ECs may cause vascular dysfunction or the late pulmonary fibrosis.
Our finding that EndMT occurs during the development of RIPF led us to wonder how the early EC damage triggers the radiation-induced late effects, such as vascular fibrosis (Fig.   1B) . We observed that vascular ECs (specifically) were positive for a hypoxic marker, CA9, before substantial fibrogenesis was evident (Fig. 3A and B) . It thus appeared that hypoxic damage might induce EndMT, thereby forming fibroblasts that cause lung fibrogenesis (Fig.   3C-F and Fig. 4 ). In our previous reports (16), we showed that when lung tissues of mice were irradiated with 90 Gy (a 3-mm-diameter field), severe hemorrhage with vascular destruction was evident, and the arterial wall thickness increased in 9 days. Increased alveolar wall thickness and destruction were evident after 5 and 7 days, respectively (16) . After delivery of 20 Gy of irradiation (a 7-mm-diameter field), fibrosis developed about 6 months later. We therefore hypothesize that direct vascular damage or chronic inflammatory response may trigger vascular dysfunction, leading to tissue hypoxia. Concomitant with the development of vascular dysfunction in irradiated lung tissues, vascular ECs may become hypoxic and specifically positive for CA-9 or HIF1-α in the early phase of RIPF development (Fig. 3A and B) .
Research. In this respect, Fleckenstein et al. suggested that radiation-induced hypoxia in lung tissues is caused, in part, by increased oxygen consumption by macrophages, which are activated due to radiation-induced reductions in blood perfusion (7). Also, it was shown that the initial tissue hypoxia was followed by chronic oxidative stress in irradiated lung tissue, suggesting that hypoxia is one of the driving forces in initiating irradiation-induced lung injury (7). Vujaskovic et al. also reported that hypoxia was important in triggering continuous production of fibrogenic cytokines and perpetuation of late lung tissue injury (37) .
Relevant to our finding of radiation-induced EndMT during RIPF development, several reports have described EMT-associated RIPF (9, 10). We found that in the development of RIPF, vascular EndMT appeared prior to an EMT ( Fig. 1 and Supplementary   Fig. S2 ). The EMT during development of RIPF was principally in alveolar ECs. The different time course for the occurrence of EndMT and EMT lead us to hypothesize that the initial vascular hypoxic damage after irradiation may propagate to lung tissue, including alveoli, and that EMT in alveolar epithelial cells may be indirectly caused by both fibrogenic cytokines released during the EndMT and hypoxia, apart from the direct damage to alveolar epithelial cells caused by irradiation. In addition, we may not exclude the possibility that EMT is partially independent of EndMT. EndMT was more prominent at 90 Gy than at 20 Gy, although EMT at 20 Gy was more dominant than that at 90 Gy (Supplementary Fig. S2 ).
In addition, the mechanism by which RIPF is caused by 90 Gy irradiation may differ from the mechanism at 20 Gy, as 90 Gy irradiation induced more rapid RIPF in comparison to 20 Gy irradiation. Thus, to determine whether EndMT is a direct pathogenesis of RIPF or affects EMT occurrence, we are now studying RIPF in genetically engineered mouse models with modified EC-specific genes that regulate EndMT.
It has been shown that targeting TGF-β receptor Ι/Smad3 signaling, and downstream targets such as Snail 1, inhibits EndMT under pathologic conditions (12) . In the present work, 
we also found that the irradiation-induced EndMT was regulated by TGF-β receptor Ι/ Smad signaling. Moreover, the EndMT caused by hypoxia was triggered by such signaling, in association with increased expression of HIF-1α. Thus, the irradiation-induced EndMT triggered by TGF-β receptor Ι/Smad signaling could be affected by knockdown of HIF-1α (Fig. 3) TGF-β receptor (ALK5) kinase activity has recently been reported to require high-level HIF-1α expression in response to TGF-β1 (38) . Several reports have suggested that TGF-β and HIF-1α engage in mutual regulation (38) (39) (40) . In agreement with these reports, we found that the hypoxia-induced EndMT required TGF-β receptor/Smad signaling; we found that Smad3 siRNA decreased HIF-1α expression during the hypoxia-induced EndMT whereas HIF-1α siRNA inhibited radiation-induced EndMT, accompanied by a decrease in TGF-β receptor/Smad signaling. These results suggest that, during irradiation-induced EndMT, the expression of HIF-1α is regulated both by hypoxia-induced TGF-β receptor activity and otherwise. Increases in HIF-1α levels caused by direct hypoxic stress (41) regulated TGF-β receptor/Smad3 signaling (Fig. 3) . We are now further elucidating these mutual regulatory mechanisms.
Although much effort has focused on overcoming irradiation-induced complications in normal tissues, the clinical utilities of existing drugs are limited by drug toxicity or the radioprotection of tumors (3). 2-ME, a metabolite of 17-beta-estradiol, has been shown to exert marked anti-carcinogenic properties in several malignant cell types, and Phase I/II clinical trials of 2-ME are currently underway in patients with prostate, breast, and metastatic breast cancer (42) . In the present study, we investigate the efficacy of 2-ME to inhibit RIPF because, recently, 2-ME has been suggested to effectively inhibit HIF-1α action even though 2-ME has other effects such as microtubule distruption. In vivo, 2-ME indeed inhibited the concomitant vascular collagen depositions appeared in the development of RIPF (Fig. 4) . 2-ME also reduced EMT and the substantial fibrotic phase (Supplementary Fig. S3 ). Although other investigators also reported that 2-ME enhances tumor radiosensitivity (29) (30) (31) (32) , further studies are needed for the better understanding of the potential usefulness of 2-ME to radiosensitize tumors. In addition, our studies with human tissues clearly indicated that EndMT mostly was detected on HIF-1α-positive vascular ECs in RIPF tissues and not in normal lung tissues (Fig. 5) .
In summary, we provide new insights into the pathogenesis of RIPF. We suggest that pretreated for 1 h with 0 or 10 ng/mL 2-ME and irradiated with 10 Gy. At 72 h after irradiation, the levels of phalloidin (green), CA9 (white), and VE-cadherin (red) were assessed via immunofluorescence staining (Top). Cell proteins were subjected to western blotting using the indicated antibodies (Bottom). B, C57/Bl6 mice (n=8 per group) were pretreated with 2-ME (60 mg/kg) or vehicle and the thoracic part of the left lung was 16Gy irradiated. After irradiation, 2-ME treatment was continued on 3 days per week for 2 weeks, and lung samples then obtained 1 month after irradiation. The images show representative HIF1-α immunohistochemical data, Masson's trichrome staining patterns (Scale bar = 100 µm) and co-localization (yellow pixels) of CD31 and α-SMA or HIF1-α, CD31 and α-SMA.
The graphs indicate as % of the vascular area positive for HIF-1α f total vascular area, the relative levels of vascular collagen deposition and co-localization of CD31 and α-SMA or HIF1-α, CD31 and α-SMA in vessels, from the five 100× fields (error bars indicate the SEMs of eight mice per group . 
